Welcome to our dedicated page for Cosmo Pharmaceuticals Nv news (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on Cosmo Pharmaceuticals Nv stock.
Cosmo Pharmaceuticals N.V. (CMOPF) delivers cutting-edge solutions in gastrointestinal therapies, dermatological innovations, and AI-enhanced medical devices. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical advancements, and strategic collaborations shaping the future of precision medicine.
Access authoritative reporting on earnings announcements, product approvals, and R&D breakthroughs, including developments in Cosmo's flagship technologies like the GI Genius™ AI detection system and Winlevi® acne treatment. Our curated news feed consolidates press releases, partnership disclosures, and market analyses to support informed decision-making.
Key focus areas include updates on Cosmo's MMX drug-delivery platform, progress in bile acid diarrhea treatments, and expansion of its CDMO operations. Bookmark this page for direct access to primary-source materials and objective reporting on one of healthcare's most innovative players.
Cosmo Pharmaceuticals announced its final audited results for 2023, showcasing strong growth. The company reported revenues of €92.8 million, EBITDA of €20.4 million, operating profit of €6.1 million, and a net cash inflow from operating activities of €33.6 million. Despite a net loss after taxes of €4.7 million, Cosmo remains debt-free with a net cash position of €136.1 million as of April 30, 2024. A dividend of €2.00 per share (up 90.5% from last year) will be proposed. Cosmo's partnership with Medtronic has strengthened its financial position, with a $100 million upfront payment received and another $100 million expected by the end of 2024. Key products GI Genius and Winlevi continue to perform well, while Cosmo's development pipeline progresses with several clinical trials. The company has increased its 2024 operating profit guidance by €4.4 million, anticipating operating profits between €159.4 million and €169.4 million, and total revenues between €260 million and €270 million.
On May 24, 2024, Cosmo Pharmaceuticals announced that shareholders approved all agenda items at their annual general meeting. Representing 42.28% of total outstanding shares, 7,417,916 ordinary shares were voted.
Key approvals include electing the Board members for one year, authorizing the Board to issue ordinary shares up to 10% of the nominal value for the next 18 months, and potentially up to 20% in cases of mergers or acquisitions. Additionally, shareholder approval was given to issue shares for the employee stock ownership plan and to issue preferred shares, both valid for 18 months. Furthermore, the Board was authorized to limit pre-emptive rights and buy back up to 10% of Cosmo's shares, valid for the same period.
Cosmo Pharmaceuticals N.V. has been granted an extension until 31 May 2024 to publish its 2023 annual report and file it with SIX Exchange Regulation AG. The company is finalizing accounting treatment with auditors, impacting preliminary unaudited figures. Key figures include a potential €9.0m impact on 2023 operating profit, affecting 2024 guidance.
Cosmo Pharmaceuticals N.V. invites stakeholders to a Q&A session on May 4, 2021, discussing its FDA-approved AI device, GI Genius™, designed for detecting colon cancer. This technology, also approved in Europe, Australia, Israel, and the UAE, is distributed globally through a partnership with Medtronic. Key representatives, including CEO Alessandro Della Chà and CFO Niall Donnelly, will explain how GI Genius™ addresses colorectal cancer challenges. The company focuses on gastrointestinal disorders and has partnerships for product distribution.
FAQ
What is the current stock price of Cosmo Pharmaceuticals Nv (CMOPF)?
What is the market cap of Cosmo Pharmaceuticals Nv (CMOPF)?
